Thromboelastography (TEG) is a method of testing the efficiency of blood coagulation. It is mainly used in surgery and anesthesiology. Thromboelastography (TEG) was first invented by Harter (Germany) in 1948. Now it has been widely used in many departments in the hospital. Until 2000, the TEG5000 Hemostasis Analyzer was invented by Haemonetics Corporation; It is widely used in nearly 40 countries.

Global thromboelastography (TEG) market was valued at 87 Million US$ in 2018 and is projected to reach 153 Million US$ by 2024, at a CAGR of 9.87% during the forecast period.

Before 2010, there is only one manufacture of thromboelastography (TEG), the Haemonetics Corporation, with its TEG5000 Hemostasis Analyzer, it makes a big profit in all over the world.
Now, many new manufactures are developing and producing this product. There is a huge market for all of the hospitals and more and more manufactures realize this.
As comparison between traditional coagulation test and the thromboelastography, the latter has obvious advantages:
The whole process of coagulation
Do not need to deal with blood samples, whole blood, plasma can also be OK.
Both qualitative and quantitative results, it has many different results.
International standard parameters.
So, under the expansion of globalization, interdependence of countries around the world continues to strengthen, and the relations between states increasingly close.

Key players in global thromboelastography (TEG) market include: Haemonetics Corporation, Lepu Medical, Quaero Life Science, Shaanxi Yuzeyi.